Arcus Biosciences Announces Anti-TIGIT Program Update
Company Announcements

Arcus Biosciences Announces Anti-TIGIT Program Update

Arcus Biosciences Inc (RCUS) has released an update.

The Company released a press statement on January 29, 2024, providing updates on its anti-TIGIT clinical development program.

For further insights into RCUS stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TheFlyArcus Biosciences reports Q2 EPS ($1.02), consensus ($1.10)
TheFlySagimet Biosciences appoints Phillips, Jarrett to board of directors
TheFlyArcus Biosciences price target lowered to $35 from $40 at Morgan Stanley
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!